Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study

Liu,Ning; Feng,Jiao; Lv,Yang; Liu,Qing; Deng,Jingfan; Xia,Yujing; Guo,Chuanyong; Zhou,Yingqun

doi:10.3892/etm.2019.8011

Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study

Authors:
- Ning Liu
- Jiao Feng
- Yang Lv
- Qing Liu
- Jingfan Deng
- Yujing Xia
- Chuanyong Guo
- Yingqun Zhou
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, P.R. China
Published online on: September 17, 2019 https://doi.org/10.3892/etm.2019.8011
Pages: 4058-4066
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The accumulation of toxic bile acids (BAs) is closely related to liver injury, inflammation and tumorigenesis. The aim of the present study was to determine the role of the serum BA spectrum in the diagnosis and progression of liver cirrhosis. This was a prospective observational study involving patients with chronic hepatitis (n=23), liver cirrhosis (n=101), and cirrhosis complicated with hepatocellular carcinoma (CC‑HCC; n=56). The 6‑month survival of cirrhotic patients was recorded after blood collection. Comparisons of serum total BAs and individual BAs between different groups were performed using the Mann‑Whitney U or Kruskal‑Wallis tests. Correlation analysis was conducted by Spearman's correlation. Diagnosis and prediction analyses were performed using receiver operating characteristic curves. Survival was analyzed using the Kaplan‑Meier method and multivariable Cox regression analysis. The concentrations of total BAs, glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), taurocholic acid (TCA), taurochenoxycholic acid and tauroursodeoxycholic acid (TUDCA) were increased significantly in patients with early cirrhosis compared to patients with chronic hepatitis (P<0.05) and were associated with the diagnosis of cirrhosis (P=0.049, 0.004, 0.002, 0.003, 0.010 and 0.009, respectively). The levels of total BAs, primary conjugated BAs, and TUDCA increased as liver cirrhosis progressed (P<0.05). Serum total BAs, GCA, GCDCA, and TCA predicted the 6‑month survival of patients with liver cirrhosis (P=0.0003, 0.005, 0.002, and 0.010 respectively). Based on multivariate Cox regression analysis, the level of total BAs was an independent predictor of mortality in cirrhotic patients (hazard ratios, 4.046; 95% CI, 1.620‑10.108; P=0.003). In the early‑stage cirrhosis group, the concentrations of total BAs and primary conjugated BAs were significantly elevated in patients with CC‑HCC compared with patients with cirrhosis alone. In conclusion, total and individual BAs, especially primary conjugated BAs, are effective non‑invasive markers in the diagnosis and prognosis of liver cirrhosis, and may be potential indicators in the occurrence of hepatocellular carcinoma in patients with early cirrhosis.

View Figures

View References

1	Asrani SK, Devarbhavi H, Eaton J and Kamath PS: Burden of liver diseases in the world. J Hepatol. 70:151–171. 2019. View Article : Google Scholar : PubMed/NCBI
2	Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 127((5 Suppl 1)): S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
3	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
4	Boyer JL: Bile formation and secretion. Compr Physiol. 3:1035–1078. 2013.PubMed/NCBI
5	Arab JP, Martin-Mateos RM and Shah VH: Gut-liver axis, cirrhosis and portal hypertension: The chicken and the egg. Hepatol Int. 12 (Suppl 1):S24–S33. 2018. View Article : Google Scholar
6	Meier PJ and Stieger B: Bile salt transporters. Annu Rev Physiol. 64:635–661. 2002. View Article : Google Scholar : PubMed/NCBI
7	Li T and Apte U: Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. Adv Pharmacol. 74:263–302. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang H, Shang X, Wan X, Xiang X, Mao Q, Deng G and Wu Y: Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: A retrospective cohort study. Sci Rep. 6:381802016. View Article : Google Scholar : PubMed/NCBI
9	Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG and Allard JP: Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One. 11:e01518292016. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, Yao C, Jia W and Liu P: Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis. J Proteome Res. 15:1126–1134. 2016. View Article : Google Scholar : PubMed/NCBI
11	Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, et al: Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics. 10:M110.0049452011. View Article : Google Scholar : PubMed/NCBI
12	Singal AK and Kamath PS: Model for end-stage liver disease. J Clin Exp Hepatol. 3:50–60. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kamath PS and Kim WR; Advanced Liver Disease Study Group, : The model for end-stage liver disease (MELD). Hepatology. 45:797–805. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, et al: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 124:91–96. 2003. View Article : Google Scholar : PubMed/NCBI
15	Krautbauer S and Liebisch G: LC-MS/MS analysis of bile acids. Methods Mol Biol. 1730:103–110. 2018. View Article : Google Scholar : PubMed/NCBI
16	Chong J, Yamamoto M and Xia J: MetaboAnalystR 2.0: From raw spectra to biological insights. Metabolites. 9(pii): E572019. View Article : Google Scholar : PubMed/NCBI
17	Mannes GA, Thieme C, Stellaard F, Wang T, Sauerbruch T and Paumgartner G: Prognostic significance of serum bile acids in cirrhosis. Hepatology. 6:50–53. 1986. View Article : Google Scholar : PubMed/NCBI
18	Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S and Makino I: Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology. 86:514–520. 1984.PubMed/NCBI
19	Gilmore IT and Thompson RP: Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease. Gut. 21:123–127. 1980. View Article : Google Scholar : PubMed/NCBI
20	Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, et al: Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 60:940–947. 2014. View Article : Google Scholar : PubMed/NCBI
21	Cassard AM and Ciocan D: Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol. 24:100–107. 2018. View Article : Google Scholar : PubMed/NCBI
22	Martinot E, Sèdes L, Baptissart M, Lobaccaro JM, Caira F, Beaudoin C and Volle DH: Bile acids and their receptors. Mol Aspects Med. 56:2–9. 2017. View Article : Google Scholar : PubMed/NCBI
23	Massafra V and van Mil SWC: Farnesoid X receptor: A ‘homeostat’ for hepatic nutrient metabolism. Biochim Biophys Acta Mol Basis Dis. 1864:45–59. 2018. View Article : Google Scholar : PubMed/NCBI
24	Kim SG, Kim BK, Kim K and Fang S: Bile acid nuclear receptor farnesoid X receptor: Therapeutic target for nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 31:500–504. 2016. View Article : Google Scholar : PubMed/NCBI
25	Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F and Laleman W: Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 59:2286–2298. 2014. View Article : Google Scholar : PubMed/NCBI
26	Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, et al: Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 58:949–955. 2013. View Article : Google Scholar : PubMed/NCBI
27	Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V and Gassull MA: Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 37:551–557. 2003. View Article : Google Scholar : PubMed/NCBI
28	Seo YS and Shah VH: The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol. 18:337–346. 2012. View Article : Google Scholar : PubMed/NCBI
29	Marin JJ, Macias RI, Briz O, Banales JM and Monte MJ: Bile acids in physiology, pathology and pharmacology. Curr Drug Metab. 17:4–29. 2015. View Article : Google Scholar : PubMed/NCBI
30	Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW and Van Erpecum KJ: Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta. 1801:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
31	Nuño-Lámbarri N, Barbero-Becerra VJ, Uribe M and Chávez-Tapia NC: Elevated cholesterol levels have a poor prognosis in a cholestasis scenario. J Biochem Mol Toxicol. 31:1–6. 2017. View Article : Google Scholar
32	Gong Z, Zhou J, Zhao S, Tian C, Wang P, Xu C, Chen Y, Cai W and Wu J: Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis. Oncotarget. 7:83951–83963. 2016. View Article : Google Scholar : PubMed/NCBI
33	Tripodi V, Contin M, Fernández MA and Lemberg A: Bile acids content in brain of common duct ligated rats. Ann Hepatol. 11:930–934. 2012. View Article : Google Scholar : PubMed/NCBI
34	Horvatits T, Drolz A, Rutter K, Roedl K, Fauler G, Müller C, Kluge S, Trauner M, Schenk P and Fuhrmann V: Serum bile acids in patients with hepatopulmonary syndrome. Z Gastroenterol. 55:361–367. 2017.PubMed/NCBI
35	Desai MS, Mathur B, Eblimit Z, Vasquez H, Taegtmeyer H, Karpen SJ, Penny DJ, Moore DD and Anakk S: Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart. Hepatology. 65:189–201. 2017. View Article : Google Scholar : PubMed/NCBI
36	Pak JM and Lee SS: Vasoactive effects of bile salts in cirrhotic rats: In vivo and in vitro studies. Hepatology. 18:1175–1181. 1993. View Article : Google Scholar : PubMed/NCBI
37	Desai MS and Penny DJ: Bile acids induce arrhythmias: Old metabolite, new tricks. Heart. 99:1629–1630. 2013. View Article : Google Scholar : PubMed/NCBI
38	Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D and Fagniez PL: Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: Midterm results and perspectives. Ann Surg. 243:499–506. 2006. View Article : Google Scholar : PubMed/NCBI
39	Fan M, Wang X, Xu G, Yan Q and Huang W: Bile acid signaling and liver regeneration. Biochim Biophys Acta. 1849:196–200. 2015. View Article : Google Scholar : PubMed/NCBI
40	Altamirano-Barrera A, Uribe M, Lammert F and Méndez-Sánchez N: Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis. Ann Hepatol. 15:453–454. 2016. View Article : Google Scholar : PubMed/NCBI
41	Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, et al: Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 139:1764–1775. 2016. View Article : Google Scholar : PubMed/NCBI